Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor
The molecular chaperone Hsp90 oversees the folding of many proteins associated with cancer progression but existing small-molecule inhibitors of this pathway are not isoform-selective. Here, the authors rationally design an Hsp90 inhibitor that displays high selectivity for the Hsp90β isoform.
Main Authors: | Anuj Khandelwal, Caitlin N. Kent, Maurie Balch, Shuxia Peng, Sanket J. Mishra, Junpeng Deng, Victor W. Day, Weiya Liu, Chitra Subramanian, Mark Cohen, Jeffery M. Holzbeierlein, Robert Matts, Brian S. J. Blagg |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2018-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-017-02013-1 |
Similar Items
-
High-Throughput Screen of Natural Product Libraries for Hsp90 Inhibitors
by: Jason Davenport, et al.
Published: (2014-02-01) -
Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells
by: Eskew Jeffery D, et al.
Published: (2011-10-01) -
Assessment of Hsp90β-selective inhibitor safety and on-target effects
by: Tyelor S. Reynolds, et al.
Published: (2025-01-01) -
Inhibiting spinal cord-specific hsp90 isoforms reveals a novel strategy to improve the therapeutic index of opioid treatment
by: David I. Duron, et al.
Published: (2024-06-01) -
Cytosolic Hsp90 Isoform-Specific Functions and Clinical Significance
by: Samarpan Maiti, et al.
Published: (2022-08-01)